PA-GCCA
23.9.2022 18:31:43 CEST | Business Wire | Press release
The Clean Energy Ministerial CCUS (CEM CCUS) and the Global Cement and Concrete Association (GCCA) have today, at the first-ever Global Clean Energy Action Forum (GCEAF), announced an agreement that will help scale up the deployment of carbon capture, utilisation and storage (CCUS) throughout the cement and concrete industry, in a move to stimulate innovation, investment and increase the pace of decarbonisation efforts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005359/en/
Major CCUS industry and government collaboration announced at Global Clean Energy Action Forum (GCEAF) in Pittsburgh, USA. Left to right: Thomas Guillot, CEO of the Global Cement and Concrete Association, Henriette Nesheim, Assistant Director General, Norwegian Ministry of Petroleum and Energy – and CEM CCUS Initiative Co-Lead from Norway, Brad Crabtree, Assistant Secretary, Fossil Energy and Carbon Management, US Department of Energy (Photo: Business Wire)
Central to the agreement will be exploring incentives, policy frameworks and finance solutions at a global level that can enable industrial-scale CCUS projects over the next ten years. The two organisations will work together to ensure the long-term deployment of CCUS, beyond 2030, via both policy and technological development.
The agreement sets out the role CCUS can have in safely and effectively delivering a net zero future and facilitates the identification and mapping of potential cement-sector CCUS projects. It will explore the transport and storage infrastructure needs involved in integrating cement CCUS projects into strategic CCUS transport and storage hubs. It will also help to foster project partnerships and lead to acceleration of projects in developing economies.
Thomas Guillot, CEO of the Global Cement and Concrete Association, said: “Cement is the vital ingredient in concrete, the world’s most-used human-made material. It is the backbone of the modern world. The industry is striving to innovate at every stage of the concrete life cycle. We see carbon capture as a vital lever for the global cement industry to achieve its ambitious goal of net-zero concrete by 2050.
“We are starting to see the first CCUS projects already emerge. We have mapped 35 projects announced and underway across the world and up to 100 additional projects are also in the pipeline among our member companies who operate all around the globe.”
Mr Guillot added: “This is good progress, but we cannot achieve our decarbonisation mission alone. CCUS is a key enabling technology, and it is a critical area for collaboration to ensure that government policy, enabling infrastructure and wider investment is in place. That is why the partnership with the Clean Energy Ministerial CCUS Initiative is so important, to help unlock and accelerate further progress and deployment.”
Henriette Nesheim, Assistant Director General, Norwegian Ministry of Petroleum and Energy – and CEM CCUS Initiative Co-Lead from Norway, said: “This is a great opportunity to work together with a vitally important industry. In Norway we are already building our first cement-CCS project in Brevik, and we look forward to sharing the experience with others.”
Brad Crabtree, Assistant Secretary, Fossil Energy and Carbon Management, US Department of Energy, said: “Reaching our ambitious climate goals requires the decarbonization of various heavy industries, including cement production. In the United States, through the support of Congress, we are currently funding projects to develop carbon capture technologies in cement and other key industrial sectors that are essential to modern life, with the aim of helping to achieve net-zero emissions economywide by 2050 and retaining and creating high-wage industrial jobs. The U.S. Government is keen to drive progress in this area, together with our partners in the CEM CCUS Initiative and the Global Cement and Concrete Association.”
To reach these objectives, both parties have agreed to the organisation of expert workshops, inclusive of CEM CCUS and GCCA members, as well as relevant stakeholders and partners including the CEM Industry Deep Decarbonisation Initiative (IDDI). Both parties will also produce joint reports and organise public events outlining progress in opportunities to implement CCUS projects at strategic hubs.
The agreement was announced at a GCCA and CEM CCUS led event at the Global Energy Action Forum, focused on the challenge and opportunity for CCUS as a major decarbonisation lever for the global cement and concrete sector. This aligns with a core pillar of the GCCA’s 2050 Net Zero Roadmap, launched last year, in which its members have committed to the deployment of at least ten industrial-scale CCUS projects by 2030.
At the event, the industry summarised the key challenges in accelerating the deployment of CCUS and outlined the enabling factors crucial to increasing its rollout to create a greener concrete future. These factors include supporting policies and financing, public procurement progress and CO2 infrastructure and storage options alongside strategic hubs.
-ends-
Notes to editors:
Speakers at the GCCA and CEM CCUS led event at the Global Energy Action Forum included:
- Henriette Nesheim, Assistant Director General, Norwegian Ministry of Petroleum and Energy – and CEM CCUS Initiative Co-Lead from Norway
- Dan Dorner, Head of CEM Secretariat
- Thomas Guillot, CEO, Global Cement and Concrete Association
Panel:
- Chris Ward, CEO, Lehigh Hanson Cement
- Bjorn Otto Sverdrup, ExCom Chair, OGCI
- Tareq Emtairah, Director, UNIDO
- Brad Crabtree, Assistant Secretary, Fossil Energy and Carbon Management, US Department of Energy
- Khalid Abuleif, Chief Climate Negotiator, Saudi Arabia
- Moderator: Juho Lipponen, CEM CCUS
About the GCCA
Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction. The GCCA aims to foster innovation throughout the construction value chain in collaboration with industry associations as well as architects, engineers, and innovators. The association demonstrates how concrete solutions can meet global construction challenges and sustainable development goals while showcasing responsible industrial leadership in the manufacture and use of cement and concrete. It complements and supports the work of associations at national and regional levels.
About CEM CCUS
The Clean Energy Ministerial CCUS Initiative is a group of 14 member countries who have joined forces to accelerate CCUS together. The CEM CCUS countries all develop comprehensive CCUS programmes, with the intent to decarbonise all relevant industrial sectors. The objective of the Initiative is to accelerate CCUS as a viable CO2 mitigation option, facilitate diffusions of knowledge on technologies, regulations, and policies, and lead to strategic partnerships to accelerate both near- and longer-term investment in CCUS. As an action-orientate platform, the Imitative does not perform analysis, but serves to bring government, industry and the financial and investment sectors together.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005359/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
